FGL2 Technologies

Veritas Therapeutics Inc is the world-leader in development of  diagnostic and therapeutic FGL2-based technologies  for the treatment of autoimmune diseases, transplant rejection, bacterial and viral infections, and cancer. Veritas builds on the findings that FGL2 binds to FcγRIIB/III inhibiting immune activation of innate and adaptive immunity. FGL2 proteins have been shown to be effective in treatment of rejection and tolerance induction whereas antibodies and siRNA  to FGL2 restore effective T and B cell immune responses in the setting of chronic viral infection and cancer.

News

• Veritas receives a grant to validate FGL2-based technologies for treatement of chronic viral infections
• Veritas enters into a new collaborative license agreement to commercialize technologies

Veritas Therapeutics Inc. is the newly founded commercialization arm associated with the Toronto Transplant Institute (TTI) located at the University Health Network / University of Toronto in Toronto, Ontario, Canada. TTI and its predecessor, the Multi Organ Transplant (MOT) program are the largest transplant program in Canada and one of the largest in the world.